A share price of Jazz Pharmaceuticals plc [JAZZ] is currently trading at $137.22, down -0.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JAZZ shares have gain 1.10% over the last week, with a monthly amount drifted -0.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on July 15, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $152. Previously, UBS upgraded its rating to Buy on March 07, 2025, and elevated its price target to $179. On February 26, 2025, downgrade downgraded it’s rating to Neutral. Wells Fargo upgraded its rating to an Overweight and increased its price target to $170 on February 13, 2025. Morgan Stanley upgraded its rating to an Overweight and raised its price target to $175 on December 12, 2024. Goldman started tracking with a Buy rating for this stock on June 05, 2024, and assigned it a price target of $169. In a note dated January 03, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $160 on this stock.
Jazz Pharmaceuticals plc experienced fluctuations in its stock price throughout the past year between $95.49 and $148.06. Currently, Wall Street analysts expect the stock to reach $172.2 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $137.22 at the most recent close of the market. An investor can expect a potential return of 25.49% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
Trailing Twelve Months sales for Jazz Pharmaceuticals plc [NASDAQ:JAZZ] were 4.09B which represents 2.14% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.1 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 133.88 points at the first support level, and at 130.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 140.17, and for the 2nd resistance point, it is at 143.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Jazz Pharmaceuticals plc [NASDAQ:JAZZ] is 1.62. As well, the Quick Ratio is 1.37, while the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 2.04, the price to book ratio is 2.25.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Director, that happened on Oct 03 ’25 when 3500.0 shares were sold. Director, COZADD BRUCE C completed a deal on Oct 01 ’25 to sell 2000.0 shares. Meanwhile, Officer Bruce C Cozadd bought 3500.0 shares on Oct 03 ’25.
